Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma

• Main Authors: T. A. Titova, N. S. Besova, V. A. Gorbunova, Yu. P. Kuvshinov, A. A. Filatov, A. F. Ketsba, A. A. Fedenko
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2018-07-01
• Series: Медицинский совет
• Subjects: advanced gastric cancer; gastroesophageal cancer; second-line therapy; ramucirumab; paclitaxel; bleeding
• Online Access: https://www.med-sovet.pro/jour/article/view/2548

Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2. In two randomised clinical trials Ramucirumab either alone or in combination with paclitaxel has been found to be safe and effective for patients with previously treated advanced gastric cancer. One of the serious adverse events associated with ramucirumab is bleeding.We report the case of a 56-year-old man with advanced gastric cancer located at the gastroesophageal junction with liver, pulmonary and multiple lymph node metastases, plevritis was treated with a paclitaxel plus Ramucirumab regimen. We demonstrate a case of a cardioesophageal junction bleeding due to the high efficiency of treatment. He was successfully treated with by applying only hemostatical therapy, but after stop the bleeding chemotherapy was not reintroduced. The partial response was maintained for approximately 10 months. The patient died on 28 November 2017.Chemotherapy with best supportive care for metastatic gastric cancer shown the improvement the performance status, help keep the cancer under control and help relieve symptoms during the time.